Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-01-30

Clinical Trial Update: Study of SB939 in Subjects With Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 study of the investigational drug SB939 in patients with myelofibrosis has completed, with results posted in January 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SB939 (SB-939)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloproliferative Disorders | Phase 2 | Status: COMPLETED | Results posted: 2014-01-30